SCHEMBL30201413

SCHEMBL30201413

CC1CN(C(=O)c2cnc3c(ccn3-c3ccc(C(N)=O)nc3)c2)CC(C)O1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.45
NPC1 O15118 2/20 0.42
HSD17B10 Q99714 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
VNN1 O95497 1/20 0.39
MGLL Q99685 1/20 0.38
TP53 P04637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
FGFR1 P11362 1/20 0.37
FGFR2 P21802 1/20 0.37
FGFR3 P22607 1/20 0.37
RAB9A P51151 1/20 0.36
CAMK1D Q8IU85 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30201633 0.90 HPGD (0.45) HPGDSMN1; SMN2VNN1MGLL
SCHEMBL31038243 0.84 HPGD (0.49) HPGDNPC1ALDH1A1SMN1; SMN2VNN1
SCHEMBL31038238 0.84 HPGD (0.40) HPGDNPC1HSD17B10NPSR1ALDH1A1
SCHEMBL30202246 0.84 HPGD (0.44) HPGDNPC1HSD17B10NPSR1ALDH1A1
SCHEMBL29257216 0.83 HPGD (0.52) HPGDNPC1HSD17B10NPSR1ALDH1A1
SCHEMBL23680681 0.83 HPGD (0.64) HPGDALDH1A1MGLL
SCHEMBL23680795 0.82 HPGD (0.51) HPGDSMN1; SMN2VNN1MGLL
SCHEMBL30201178 0.81 HPGD (0.42) HPGDNPC1HSD17B10NPSR1ALDH1A1
SCHEMBL31038242 0.80 HPGD (0.50) HPGDSMN1; SMN2VNN1MGLL
SCHEMBL24942616 0.80 HPGD (0.50) HPGDSMN1; SMN2VNN1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294519-A1 PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING EPIRIUM BIO INC. 2024-09-05 US disclosed
CN-118338902-A Pyrrolo [2,3-b ] pyridine PGDH inhibitors and methods of making and using the same 埃皮里姆生物股份有限公司 2024-07-12 CN disclosed
EP-4376841-A1 PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING Epirium Bio Inc. (US) 2024-06-05 EP disclosed
WO-2023009642-A1 PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING EPIRIUM BIO INC. (US) 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294519-A1 PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING HPGD, HPGDS, PTGIS HPGD 1/4885NPC1 2754/4885HSD17B10 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.